Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655760 | 1.00 | NPC1 (0.44) | NPC1LMNANPSR1UCHL1USP30 | |
| SCHEMBL657227 | 0.90 | NPC1 (0.43) | NPC1LMNANPSR1UCHL1USP30 | |
| SCHEMBL657228 | 0.90 | NPC1 (0.43) | NPC1LMNANPSR1UCHL1USP30 | |
| SCHEMBL29330281 | 0.87 | NPC1 (0.40) | NPC1LMNANPSR1UCHL1USP30 | |
| SCHEMBL29330282 | 0.84 | ACKR3 (0.42) | NPC1LMNANPSR1UCHL1L3MBTL1 | |
| SCHEMBL15240571 | 0.81 | UCHL1 (0.46) | NPC1LMNANPSR1UCHL1USP30 | |
| SCHEMBL2137255 | 0.79 | NPSR1 (0.43) | NPC1LMNANPSR1UCHL1USP30 | |
| SCHEMBL29001990 | 0.79 | NPC1 (0.58) | NPC1LMNANPSR1UCHL1USP30 | |
| SCHEMBL29001992 | 0.79 | NPC1 (0.58) | NPC1LMNANPSR1UCHL1USP30 | |
| SCHEMBL29330250 | 0.78 | UCHL1 (0.43) | NPC1LMNANPSR1UCHL1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046303-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-8067613-B2 | Benzimidazole poly(ADP ribose)polymerase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2183248-A2 | BENZIMIDAZOLE POLY (ADP RIBOSE) POLYMERASE INHIBITORS | Abbott Laboratories (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2009012280-A2 | BENZIMIDAZOLE POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | NPC1 1897/4885LMNA 302/4885NPSR1 4701/4885 |
| US-20120046303-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | NPC1 1897/4885LMNA 302/4885NPSR1 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.